CervoMed reports promising DLB trial results
BOSTON – CervoMed Inc. (NASDAQ: CRVO), a biopharmaceutical company specializing in neurological disorders, announced significant findings from its Phase 2a AscenD-LB trial for the treatment of dementia with Lewy bodies (DLB).
The trial’s results, which were presented at the Alzheimer’s Association International Conference in Philadelphia, indicate that the company’s drug, neflamapimod, led to a notable reduction in plasma glial fibrillary acidic protein (GFAP) levels, which are correlated with the severity of dementia symptoms.
The study evaluated the effects of neflamapimod on patients with early-stage DLB, who do not have Alzheimer’s Disease co-pathology. In this group, neflamapimod treatment resulted in a mean decrease of 10.6 pg/mL in GFAP levels, compared to a 14.1 pg/mL increase in the placebo group. Furthermore, the reduction in GFAP was associated with improvements in clinical outcomes as measured by the Clinical Dementia Rating Sum of Boxes (CDR-SB).
GFAP has emerged as a potential biomarker for DLB, with separate research indicating its elevation in patients with prodromal DLB relative to healthy controls. CervoMed’s CEO, John Alam, MD, highlighted the clear association between plasma GFAP and dementia severity, emphasizing the potential of neflamapimod to address the underlying disease process in DLB.
The ongoing RewinD-LB Phase 2b study, a randomized trial funded by a $21.0 million grant from the National Institute on Aging, is evaluating neflamapimod in up to 160 patients with mild DLB. The study, which completed enrollment in June 2024, aims to provide further evidence of the drug’s efficacy, with topline results expected in December 2024.
CervoMed’s press release also contains forward-looking statements regarding the potential benefits of neflamapimod and the anticipated progress of clinical trials. However, these statements are subject to risks and uncertainties that could affect the actual outcomes.
The information in this article is based on a press release statement from CervoMed Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
